PCSK9
ENSG00000169174
Target class
Enzyme
Chromosome
1
Approved drugs
2
Clinical candidates (approved and in development)
9
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- PCSK9
- Gene name
- Proprotein convertase subtilisin/kexin type 9
- Gene symbol
- PCSK9
- Previous gene symbols
- HCHOLA3
- Protein name
- Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9)
- NARC-1
- FH3
- Gene biotype
- Protein coding
- Gene family
- Proprotein convertase subtilisin/kexin family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 13
- Highest tissue expression
- 25.55
- Tissue specificity (Gini)
- 0.857
- Tissue specificity (tau)
- 0.944
- KEGG gene identifiers
- hsa:255738
- Protein interaction confidence
- 0.81229
- Protein interaction partners
- 31
- R-HSA-381426
- R-HSA-8866427
- R-HSA-8957275
- R-HSA-8964038
- End position
- 55064852
- Start position
- 55039445
- Chromosome
- 1
- Strand
- Forward
- Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Note=Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein. Localizes to the endoplasmic reticulum in the absence of LDLR and colocalizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation.
- Tissue specificity (tau)
- 0.943529
- Expression inequality (Gini)
- 0.857301
Expression in transcripts per million
- Liver
- 25.55
- Brain - Cerebellar Hemisphere
- 23.5
- Brain - Cerebellum
- 22.15
- Lung
- 6.74
- Esophagus - Mucosa
- 4.94
Expression in transcripts per million
- Liver25.55
- Brain - Cerebellar Hemisphere23.5
- Brain - Cerebellum22.15
- Lung6.74
- Esophagus - Mucosa4.94
- Small Intestine - Terminal Ileum2.89
- Pancreas2.68
- Nerve - Tibial1.82
- Colon - Transverse1.63
- Skin - Sun Exposed (Lower leg)1.49
- Vagina1.21
- Skin - Not Sun Exposed (Suprapubic)1.19
- Testis1.1
- Cells - Cultured fibroblasts0.54
- Stomach0.33
- Kidney - Medulla0.28
- Adipose - Visceral (Omentum)0.27
- Whole Blood0.25
- Brain - Nucleus accumbens (basal ganglia)0.22
- Spleen0.2
- Artery - Aorta0.2
- Fallopian Tube0.19
- Esophagus - Muscularis0.16
- Cervix - Ectocervix0.15
- Bladder0.15
And 29 more, listed on the interactive page.
- GO:0001920
- GO:0002091
- GO:0002092
- GO:0007041
- GO:0010989
- GO:0016540
- GO:0032802
- GO:0032805
- GO:0042632
- GO:0043525
- GO:1903783
- GO:1905601
- GO:0005576
- GO:0005737
- GO:0005764
- GO:0005765
- GO:0005769
- GO:0005770
- GO:0005783
- GO:0005788
- GO:0005794
- GO:0005886
- GO:0009986
- GO:0031232
- GO:0036020
- GO:0048471
- GO:1990666
- GO:1990667
- GO:0003723
- GO:0004175
- GO:0004252
- GO:0005515
- GO:0019871
- GO:0030547
- GO:0034190
- GO:0050750
- GO:0070326
- GO:0141110
Related records
Trials (384)
- A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
- A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
- A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis
- A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
- A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
- A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
- A Pharmacokinetic Study of JS002 in Healthy Subjects
- A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
- A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
- A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects
- A Study Explore JS001+JS002 in Patients With Advanced Cancer
- A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
Drugs (11)
- Alirocumab Subtilisin/kexin type 9 inhibitor
- Bococizumab Subtilisin/kexin type 9 inhibitor
- Evolocumab Subtilisin/kexin type 9 inhibitor
- Frovocimab Subtilisin/kexin type 9 inhibitor
- Inclisiran PCSK9 mRNA RNAi inhibitor
- Inclisiran sodium PCSK9 mRNA rnai inhibitor
- Lerodalcibep Subtilisin/kexin type 9 inhibitor
- Ongericimab Subtilisin/kexin type 9 inhibitor
- Ralpancizumab Subtilisin/kexin type 9 inhibitor
- RG-7652 Subtilisin/kexin type 9 inhibitor
- Tafolecimab Subtilisin/kexin type 9 inhibitor